Infliximab for patients with refractory ulcerative colitis

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Severe ulcerative colitis (UC) refractory to conventional therapies presents limited treatment options.
• Intravenous cyclosporine and colectomy are current options but have significant toxicity and morbidity.
• A need exists for effective therapies to manage steroid-refractory UC and avoid colectomy.

Purpose of the Study:

• To investigate the efficacy of infliximab in patients with severe, active, corticosteroid-refractory ulcerative colitis (UC).
• To assess infliximab's impact on clinical, endoscopic, and histologic outcomes.
• To determine if infliximab can reduce the need for colectomy in refractory UC patients.

Main Methods:

• A cohort of 16 patients with severe active UC refractory to conventional therapy received a single infliximab infusion (5 mg/kg).
• Seven patients were initially candidates for colectomy due to medical failure.
• Efficacy was evaluated through clinical response, endoscopic healing, histologic scores, and corticosteroid withdrawal.

Main Results:

• Infliximab treatment led to clinical, endoscopic, and histologic improvement in 88% of patients.
• Surgery was avoided in 86% of patients who were initially considered for colectomy.
• Corticosteroid therapy was discontinued in most patients, and remission was maintained for up to 10 months.

Conclusions:

• Infliximab demonstrates significant efficacy in improving clinical, endoscopic, and histologic outcomes in severe refractory UC.
• Infliximab therapy can spare patients from colectomy and allow for corticosteroid withdrawal.
• Infliximab represents a viable therapeutic option for managing severe corticosteroid-refractory ulcerative colitis.